D-0489-2023 Class II Terminated

Recalled by Azurity Pharmaceuticals, Inc. — Wilmington, MA

Recall Details

Product Type
Drugs
Report Date
April 12, 2023
Initiation Date
February 15, 2023
Termination Date
December 4, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 16,471 vials; b) 43,096 vials

Product Description

Testosterone Cypionate Injection, USP, CIII, 200 mg/mL, packaged in: a) 10 mL multiple-dose vials (NDC 52536-625-10) and b) 1 mL single dose vials (NDC 52536-625-01), Rx only, Mfd for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328.

Reason for Recall

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Distribution Pattern

US Nationwide

Code Information

Lot #23804.034A, 23803.061A, Exp 9/2024